iVeena Delivery Systems
Salt Lake City, US · Founded 2014 · Delaware corporation
iVeena Delivery Systems is a clinical-stage ophthalmology company developing pharmacologic eye-drop therapies for refractive eye diseases, including IVMED-80 for keratoconus and IVMED-85 for pediatric myopia. Its lead keratoconus asset has been licensed to Glaukos Corporation.
BiotechHealthtechMedical Devices
Founders & leadership
GS
Gerald SimmonsExecutive Officer
DR
David RobinsonDirector
NW
Ned WeinshenkerExecutive Officer, Director
JJ
James JensenDirector
GJ
Greg JonesDirector
BA
Balamurali AmbatiExecutive Officer, Director
Reported raises · per SEC filings
Form D private placements▶$2.1MraisedJul 2020 · PharmaceuticalsRule 506(c)
▶$2.1MraisedJul 2020 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Jayakrishna AmbatiDirector
- Barry HanoverDirector
- Ned WeinshenkerExecutive Officer, Director
- Heffernan RonDirector
- Robert DempseyDirector
- Gerald SimmonsExecutive Officer, Director
- Balamurali AmbatiExecutive Officer, Director
- James U JensenDirector
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Minimum investment
- $10K
- Proceeds to insiders
- $200K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.5MofferedDec 2017 · PharmaceuticalsRule 506(b)
▶$2.5MofferedDec 2017 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald SimmonsExecutive Officer, Director
- James U JensenDirector
- Jayakrishna AmbatiDirector
- Balamurali AmbatiExecutive Officer, Director
- Ned WeinshenkerExecutive Officer, Director
- Barry HanoverDirector
- Offering amount
- $2.5M
- Minimum investment
- $10K
- Proceeds to insiders
- $100K
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MofferedDec 2016 · PharmaceuticalsRule 506(b)
▶$1MofferedDec 2016 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David RobinsonDirector
- Gerald SimmonsExecutive Officer, Director
- Balamurali AmbatiExecutive Officer, Director
- Ned WeinshenkerDirector
- James JensenDirector
- Jayakrishna AmbatiDirector
- Barry HanoverDirector
- Offering amount
- $1M
- Proceeds to insiders
- $214K
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10KraisedMay 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$10KraisedMay 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald SimmonsExecutive Officer
- David RobinsonDirector
- Ned WeinshenkerExecutive Officer, Director
- James JensenDirector
- Greg JonesDirector
- Balamurali AmbatiExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $10K
- Minimum investment
- $10K
- Proceeds to insiders
- $100K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $345K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Science Foundation | Phase I | 2017 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $216.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.